BioCryst Q4 ORLADEYO rev $124.2M (+36.6%); FY2025 guidance raised; faces generic challenge

BIOCRYST PHARMACEUTICALS INC

2024-FY EPS reported -$0.43 revenue$450,712,000

Q4 ORLADEYO net revenue $124.2M (+36.6% YoY); full year 2024 net revenue $437.7M (+34.3% YoY).
FY 2024 GAAP operating loss $2.5M; non-GAAP operating profit $62.9M (excl. stock-based comp).
FY 2025 ORLADEYO revenue guidance raised to $535-550M from $515-535M; expects positive EPS in 2H 2025.
Annora Pharma filed ANDA for generic ORLADEYO; company intends to vigorously defend three patents expiring 2039.
NDA submission in 2025 for pediatric ORLADEYO granule (ages 2-11); initial data from BCX17725 and avoralstat expected by year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.